Bibliographic Details
| Title: |
The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up. |
| Authors: |
Abdallah, Nadine1 (AUTHOR), Dispenzieri, Angela1 (AUTHOR), Muchtar, Eli1 (AUTHOR), Buadi, Francis K.1 (AUTHOR), Kapoor, Prashant1 (AUTHOR), Lacy, Martha Q.1 (AUTHOR), Hwa, Yi L.1 (AUTHOR), Fonder, Amie1 (AUTHOR), Hobbs, Miriam A.1 (AUTHOR), Hayman, Suzanne R.1 (AUTHOR), Leung, Nelson1,2 (AUTHOR), Dingli, David1 (AUTHOR), Go, Ronald S.1 (AUTHOR), Lin, Yi1 (AUTHOR), Gonsalves, Wilson I.1 (AUTHOR), Binder, Moritz1 (AUTHOR), Kourelis, Taxiarchis1 (AUTHOR), Warsame, Rahma1 (AUTHOR), Kyle, Robert A.1 (AUTHOR), Rajkumar, S. Vincent1 (AUTHOR) |
| Source: |
Amyloid. Sep2023, Vol. 30 Issue 3, p261-267. 7p. |
| Subject Terms: |
*DOXYCYCLINE, *AMYLOIDOSIS |
| Abstract: |
The current treatment paradigm of AL amyloidosis lacks effective fibril-directed therapies. Doxycycline has been shown to have anti-fibril properties in preclinical models. In 2012, we reported that posttransplant prophylaxis with doxycycline was associated with improved survival compared to penicillin in patients with haematologic response. We provide here updated results after long-term follow up. We included 553 patients who underwent transplant between July 24th, 1996, and June 24th, 2014. Doxycycline 100 mg daily was used for prophylaxis in patients with penicillin allergy; since 2013, doxycycline was used as the standard for prophylaxis. Prophylaxis was typically continued for a year after transplant. The median follow-up from transplant was 12.7 years. Doxycycline was used for prophylaxis in 33% of patients; the rest received penicillin. The median time to next treatment was 6.0 (95%CI; 4.4–8.8) years and 6.0 (95%CI; 4.9–7.1) years in the doxycycline and penicillin groups, respectively (p =.89). The median overall survival was 12.0 (95%CI: 11.0–19.6) years and 11.0 (95%CI: 9.6–12.7) years in the 2 groups, respectively (p =.17). There was a minimal trend towards improved survival with doxycycline among patients with ≥ very good partial response and among patients with organ response that was not statistically significant. After long-term follow-up, there is no clear evidence to support benefit of doxycycline in the post-transplant setting. [ABSTRACT FROM AUTHOR] |
|
Copyright of Amyloid is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
